APIMEDS PHARMACEUTICALS US I (APUS) Stock Fundamental Analysis

USA • NYSE Arca • NYSEARCA:APUS • US03771D1028

1.91 USD
+0.06 (+3.24%)
Last: Feb 2, 2026, 03:07 PM
Fundamental Rating

3

Taking everything into account, APUS scores 3 out of 10 in our fundamental rating. APUS was compared to 524 industry peers in the Biotechnology industry. While APUS has a great health rating, there are worries on its profitability. APUS does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • In the past year APUS has reported negative net income.
APUS Yearly Net Income VS EBIT VS OCF VS FCFAPUS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 -200K -400K -600K -800K -1M

1.2 Ratios

  • The Return On Assets of APUS (-13.18%) is better than 81.49% of its industry peers.
  • The Return On Equity of APUS (-14.27%) is better than 86.26% of its industry peers.
Industry RankSector Rank
ROA -13.18%
ROE -14.27%
ROIC N/A
ROA(3y)-7193.47%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
APUS Yearly ROA, ROE, ROICAPUS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 0 -2K -4K -6K -8K -10K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for APUS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
APUS Yearly Profit, Operating, Gross MarginsAPUS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

  • Compared to 1 year ago, APUS has about the same amount of shares outstanding.
  • APUS has a worse debt/assets ratio than last year.
APUS Yearly Shares OutstandingAPUS Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 2M 4M 6M 8M 10M
APUS Yearly Total Debt VS Total AssetsAPUS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 200K 400K 600K

2.2 Solvency

  • APUS has an Altman-Z score of 16.96. This indicates that APUS is financially healthy and has little risk of bankruptcy at the moment.
  • With an excellent Altman-Z score value of 16.96, APUS belongs to the best of the industry, outperforming 87.98% of the companies in the same industry.
  • APUS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 16.96
ROIC/WACCN/A
WACCN/A
APUS Yearly LT Debt VS Equity VS FCFAPUS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 -500K -1M

2.3 Liquidity

  • A Current Ratio of 12.79 indicates that APUS has no problem at all paying its short term obligations.
  • APUS's Current ratio of 12.79 is amongst the best of the industry. APUS outperforms 87.79% of its industry peers.
  • A Quick Ratio of 12.79 indicates that APUS has no problem at all paying its short term obligations.
  • With an excellent Quick ratio value of 12.79, APUS belongs to the best of the industry, outperforming 87.79% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 12.79
Quick Ratio 12.79
APUS Yearly Current Assets VS Current LiabilitesAPUS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 200K 400K 600K 800K 1M

More info and screens

0

3. Growth

3.1 Past

  • The earnings per share for APUS have decreased strongly by -78.72% in the last year.
EPS 1Y (TTM)-78.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • APUS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
APUS Price Earnings VS Forward Price EarningsAPUS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
APUS Per share dataAPUS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 0.4 0.6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

  • APUS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

APIMEDS PHARMACEUTICALS US I / APUS FAQ

What is the ChartMill fundamental rating of APIMEDS PHARMACEUTICALS US I (APUS) stock?

ChartMill assigns a fundamental rating of 3 / 10 to APUS.


What is the valuation status of APIMEDS PHARMACEUTICALS US I (APUS) stock?

ChartMill assigns a valuation rating of 0 / 10 to APIMEDS PHARMACEUTICALS US I (APUS). This can be considered as Overvalued.


What is the profitability of APUS stock?

APIMEDS PHARMACEUTICALS US I (APUS) has a profitability rating of 2 / 10.


How financially healthy is APIMEDS PHARMACEUTICALS US I?

The financial health rating of APIMEDS PHARMACEUTICALS US I (APUS) is 8 / 10.